カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別

【英語タイトル】Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV280）・商品コード：GRV23NOV280
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：80
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

ペプチド薬物複合体（PDC）市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界のペプチド薬物複合体（PDC）市場は2030年までに42億1000万ドルに達し、予測期間中のCAGRは28.58%を記録する見込みです。同市場の成長は、世界的な癌患者の急増とそれに関連する死亡率、ペプチド薬物複合体（PDC）の強力な臨床試験パイプライン、および低分子化学療法剤に関連する制御不能な毒性などの既存製品の関連副作用に起因しています。

WHOによると、がんは疾病関連死の世界的な主要原因です。2020年には、世界で約1,000万人、米国では600万人以上ががんによる死亡を記録しています。さらに、cancer.govによると、2040年までに年間の新規がん患者数は2,900万人に達し、がん関連死亡者数は1,600万人に達すると推定されています。従って、制御不能な細胞増殖を標的とするPDCのような新規治療に対する需要の高まりが、ペプチド薬物複合体（PDC）市場の成長を促進すると予想されます。

現在、Lutathera（Lu 177 dotatate）とPepaxto（Melflufen）は、制御不能な細胞増殖を治療するためにFDAに承認された2つのPDCです。市場では、成人のソマトスタチン受容体陽性胃腸膵神経内分泌腫瘍を適応症とするFDA承認のPDCとして、ノバルティスのルタセラ（ルテチウムLu 177）があります。その後、2021年2月にオンコペプチド社は、多発性骨髄腫を適応症とするペパクスト（メルファラン）のFDAによる早期承認を発表しました。この領域には限られたPDCしか存在しないため、成長のための収益機会を提供することができます。

さらに、強固な臨床試験パイプラインの存在と新規PDCの発売が見込まれることも、予測期間中の市場成長を後押しすると予想されます。これらの背景には、脳腫瘍を対象とした第3相臨床試験中のPDC ANG1005、肺がんを対象とした第2相臨床試験中のPDC BT5528とBT1718があります。CBX-12も小細胞肺がんを適応症とするフェーズ2のPDC候補です。

主要企業は、共同研究、M&A、契約などの戦略的イニシアチブを金融投資とともに実施しており、これが市場の成長を促進しています。例えば、2021年12月、Coherent BiopharmaとWuXi STAは、ペプチド薬物複合体（PDC）を含む現在および将来の治療薬を開発するための戦略的パートナーシップ契約を発表しました。

ペプチド薬物複合体（PDC）市場レポートハイライト

- 製品別では、初めて承認されたPDCと、これらの医薬品に高い需要をもたらしている癌患者の世界的な増加により、ルタセラ部門が2022年の市場で最大シェアを占めました。

- タイプ別では、腫瘍細胞を標的とする治療薬として承認されたPDCであるルタセラとペパクストの存在により、治療薬セグメントが2022年のペプチド薬物複合体（PDC）市場を独占しています。

- 北米は、新たながん症例の増加や関連する複雑性、新規治療に対する医療従事者の意識の高さなどの要因により、2022年の世界市場を席巻しました。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界のペプチド薬物複合体（PDC）市場：タイプ別予測・動向分析
第5章. 世界のペプチド薬物複合体（PDC）市場：製品別予測・動向分析
第6章. 世界のペプチド薬物複合体（PDC）市場：地域別予測・動向分析
第7章. 競争状況
第8章. 結論

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Regional Scope
1.1.2 Market Definitions
1.1.3 Estimates and Forecast Timeline
1.2 Objectives
1.2.1 Objective – 1
1.2.2 Objective – 2
1.2.3 Objective – 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 GVR’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country wise market estimation using bottom-up approach
1.8 List of Secondary Sources
1.9 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Product and Type Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Peptide Drug Conjugates Market Variables, Trends, and Scope
3.1 Peptide Drug Conjugates Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Cancer Prevalence and Related Mortality
3.2.1.1.1 Cancer Incidence Data
3.2.1.2 Robust Clinical Trial Pipeline
3.2.2 Market Restraint Analysis
3.2.2.1 Long R&D Time and Slow Clinical Development Process
3.3 Peptide Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTLE Analysis
3.4 Pipeline Analysis
Chapter 4 Peptide Drug Conjugates Market – Segment Analysis, by Type, 2018 – 2030 (USD Million)
4.1 Peptide Drug Conjugates Market: Type Movement Analysis
4.2 Peptide Drug Conjugates Market Estimates & Forecast, By Type (USD Million)
4.2.1 Therapeutics
4.2.2 Diagnostics
Chapter 5 Peptide Drug Conjugates Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Peptide Drug Conjugates Market: Product Movement Analysis
5.2 Peptide Drug Conjugates Market Estimates & Forecast, By Product (USD Million)
5.2.1 OctreoScan
5.2.2 Lutathera
5.2.3 Pepaxto/ Melflufen
5.2.4 ANG1005
5.2.5 BT1718
Chapter 6 Peptide Drug Conjugates Market: Regional Estimates and Trend Analysis by Product and Type, 2018 – 2030 (USD Million)
6.1 Peptide Drug Conjugates Market: Regional Outlook
6.2 North America
6.2.1 North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.2.4 Competitive/Market Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.2.3.4 Competitive/Market Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 Target Disease Prevalence
6.3.2.3 UK Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2.4 Competitive/Market Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Target Disease Prevalence
6.3.3.3 Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.3.4 Competitive/Market Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 Target Disease Prevalence
6.3.4.3 France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.4.4 Competitive/Market Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Spain
6.3.5.1 Key Country Dynamics
6.3.5.2 Target Disease Prevalence
6.3.5.3 Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.5.4 Competitive/Market Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Italy
6.3.6.1 Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.6.2 Competitive/Market Scenario
6.3.6.3 Regulatory Framework
6.3.6.4 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Target Disease Prevalence
6.3.7.3 Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.7.4 Competitive/Market Scenario
6.3.7.5 Regulatory Framework
6.3.7.2 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Target Disease Prevalence
6.3.8.3 Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.8.4 Competitive/Market Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Target Disease Prevalence
6.3.9.3 Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.9.4 Competitive/Market Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Target Disease Prevalence
6.4.2.3 Japan Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.2.4 Competitive/Market Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 Target Disease Prevalence
6.4.3.3 China Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.3.4 Competitive/Market Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 Target Disease Prevalence
6.4.4.3 India Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.4.4 Competitive/Market Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Target Disease Prevalence
6.4.5.3 Australia Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.5.4 Competitive/Market Scenario
6.4.5.5 Regulatory Framework
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.6.3 Competitive/Market Scenario
6.4.6.4 Regulatory Framework
6.4.6.5 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4.7.3 Competitive/Market Scenario
6.4.7.4 Regulatory Framework
6.4.7.5 Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Target Disease Prevalence
6.5.2.3 Brazil Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2.4 Competitive/Market Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Target Disease Prevalence
6.5.3.3 Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.3.4 Competitive/Market Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Target Disease Prevalence
6.5.4.3 Argentina Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.4.4 Competitive/Market Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6 MEA
6.6.1 MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 Target Disease Prevalence
6.6.2.3 South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2.4 Competitive/Market Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Target Disease Prevalence
6.6.3.3 Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.3.4 Competitive/Market Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 Target Disease Prevalence
6.6.4.3 UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.4.4 Competitive/Market Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Target Disease Prevalence
6.6.5.3 Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.5.4 Competitive/Market Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Mapping
7.1.1 New Launches
7.1.2 Collaboration
7.1.3 Partnership
7.1.4 Others
7.2 Company Profiles
7.2.1 Novartis AG.
7.2.1.1 Company Overview
7.2.1.2 Financial Performance
7.2.1.3 Product Benchmarking
7.2.1.4 Strategic Initiatives
7.2.2 Bicycle Therapeutics
7.2.2.1 Company Overview
7.2.2.2 Financial Performance
7.2.2.3 Product Benchmarking
7.2.2.4 Strategic Initiatives
7.2.3 AstraZeneca
7.2.3.1 Company Overview
7.2.3.2 Financial Performance
7.2.3.3 Product Benchmarking
7.2.3.4 Strategic Initiatives
7.2.4 Cybrexa Therapeutics
7.2.4.1 Company Overview
7.2.4.2 Financial Performance
7.2.4.3 Product Benchmarking
7.2.4.4 Strategic Initiatives
7.2.5 Oncopeptides Inc.
7.2.5.1 Company Overview
7.2.5.2 Financial Performance
7.2.5.3 Product Benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 Angiochem Inc.
7.2.6.1 Company Overview
7.2.6.2 Financial Performance
7.2.6.3 Product Benchmarking
7.2.7 Innovasium Soricimed Biopharma
7.2.7.1 Company Overview
7.2.7.2 Financial performance
7.2.7.3 Product Benchmarking
7.2.7.4 Strategic Initiatives
7.2.8 Theratechnologies
7.2.8.1 Company Overview
7.2.8.2 Financial performance
7.2.8.3 Product Benchmarking
7.2.8.4 Strategic Initiatives
Chapter 8 Conclusion

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 15 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 18 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 19 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 20 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 21 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 22 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 23 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 24 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 25 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 26 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 27 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 28 Denmark Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 29 Denmark Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 30 Sweden Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 31 Sweden Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 32 Norway Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 33 Norway Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 37 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 38 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 39 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 40 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 41 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 42 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 43 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 44 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 45 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 46 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 47 Thailand Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 48 Thailand Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 49 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 50 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 51 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 52 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 53 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 54 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 55 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 56 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 57 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 60 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 63 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 64 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 65 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 66 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 67 Kuwait Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 68 Kuwait Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Peptide drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and type segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Peptide Therapeutic Market (USD Billion)
Fig. 12 Market dynamics
Fig. 13 Peptide-drug conjugates against cancer in different developmental phases are listed in the table below
Fig. 14 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
Fig. 15 Clinical trial pipeline for PDCs
Fig. 16 Porter’s five forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Clinical trials in PDCs
Fig. 19 Peptide therapeutics market: Type outlook and key takeaways
Fig. 20 Peptide therapeutics market: Type movement analysis
Fig. 21 Therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Peptide therapeutics market: Product outlook and key takeaways
Fig. 24 Peptide therapeutics market: Product movement analysis
Fig. 25 OctreoScan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Lutathera market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Pepaxto/Melflufen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 ANG1005 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 BT1718 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Peptide drug conjugates market revenue, by region, 2022 & 2030, USD Million
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key Country Dynamics
Fig. 35 Target disease prevalence
Fig. 36 U.S. peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Key Country Dynamics
Fig. 38 Target disease prevalence
Fig. 39 Canada peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key Country Dynamics
Fig. 42 Target disease prevalence
Fig. 43 UK peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key Country Dynamics
Fig. 45 Target disease prevalence
Fig. 46 Germany peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Key Country Dynamics
Fig. 48 Target disease prevalence
Fig. 49 France peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key Country Dynamics
Fig. 51 Target disease prevalence
Fig. 52 Spain peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Italy Peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key Country Dynamics
Fig. 55 Target disease prevalence
Fig. 56 Denmark peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key Country Dynamics
Fig. 58 Target disease prevalence
Fig. 59 Sweden peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key Country Dynamics
Fig. 61 Target disease prevalence
Fig. 62 Norway Peptide Drug Conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Asia Pacific peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key Country Dynamics
Fig. 66 Target disease prevalence
Fig. 67 Japan peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Target disease prevalence
Fig. 70 China peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key Country Dynamics
Fig. 72 Target disease prevalence
Fig. 73 India peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key Country Dynamics
Fig. 75 Target disease prevalence
Fig. 76 Australia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key Country Dynamics
Fig. 78 Thailand peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key Country Dynamics
Fig. 80 South Korea peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Rest of Asia Pacific peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key Country Dynamics
Fig. 84 Target disease prevalence
Fig. 85 Brazil peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key Country Dynamics
Fig. 87 Target disease prevalence
Fig. 88 Mexico peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key Country Dynamics
Fig. 90 Target disease prevalence
Fig. 91 Argentina peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key Country Dynamics
Fig. 95 Target disease prevalence
Fig. 96 South Africa peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Key Country Dynamics
Fig. 98 Target disease prevalence
Fig. 99 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key Country Dynamics
Fig. 101 Target disease prevalence
Fig. 102 UAE peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key Country Dynamics
Fig. 104 Target disease prevalence
Fig. 105 Kuwait peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 107 Key company categorization
Fig. 108 Company market share analysis, 2022
Fig. 109 Strategic framework

★調査レポート[世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別] (コード：GRV23NOV280)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のペプチド薬物複合体（PDC）市場2022-2029：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他パイプライン製品）、種類別、地域別
  • 世界の網膜静脈閉塞症治療市場（2023-2030）：エンドユーザー別（小売薬局、病院・診療所）、疾患種類別（CRVO、BRVO）、治療薬別（抗VEGF薬、副腎皮質ステロイド薬）、地域別
  • 世界のロボット支援内視鏡市場（2023-2030）：用途別（病院、外来施設）、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）
  • 世界の尿路感染症検査市場（2023-2030）：種類別（尿道炎、膀胱炎、腎盂腎炎）、エンドユーザー別（レファレンスラボラトリー、一般開業医、泌尿器科医）、地域別
  • 世界の前立腺がん診断薬市場（2023-2030）：検査種類別（予備検査、確認検査）、種類別（腺がん、間質細胞がん）、エンドユーザー別（病院、外来施設）、地域別
  • 世界の新生児スクリーニング市場（2023-2030）：技術別（タンデム質量分析、パルスオキシメトリ）、検査種類別、製品別（装置、試薬）、地域別
  • 世界の鉄欠乏性貧血（IDA）治療市場（2023-2030）：治療種類別（経口鉄剤治療、非経口鉄剤治療）、年齢層別、エンドユーザー別、地域別
  • 世界のペプチドマイクロアレイ市場2023-2030：用途別（疾患診断、タンパク質機能解析）、種類別（機器、サービス）、エンドユーザー別、地域別
  • 世界の神経バイオマーカー市場（2023-2030）：用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症）、種類別、エンドユーザー別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆